These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694 [TBL] [Abstract][Full Text] [Related]
26. UBE3A expression during early postnatal brain development is required for proper dorsomedial striatal maturation. Rotaru DC; Wallaard I; de Vries M; van der Bie J; Elgersma Y JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810252 [TBL] [Abstract][Full Text] [Related]
28. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045 [TBL] [Abstract][Full Text] [Related]
29. Enhanced Nociception in Angelman Syndrome Model Mice. McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574 [TBL] [Abstract][Full Text] [Related]
30. Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome. Mulherkar SA; Jana NR Neurobiol Dis; 2010 Dec; 40(3):586-92. PubMed ID: 20696245 [TBL] [Abstract][Full Text] [Related]
31. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations. Bossuyt SNV; Punt AM; de Graaf IJ; van den Burg J; Williams MG; Heussler H; Elgersma Y; Distel B Hum Mol Genet; 2021 Apr; 30(6):430-442. PubMed ID: 33607653 [TBL] [Abstract][Full Text] [Related]
32. Activity-dependent changes in MAPK activation in the Angelman Syndrome mouse model. Filonova I; Trotter JH; Banko JL; Weeber EJ Learn Mem; 2014 Jan; 21(2):98-104. PubMed ID: 24434871 [TBL] [Abstract][Full Text] [Related]
33. Expression of the Rho-GEF Pbl/ECT2 is regulated by the UBE3A E3 ubiquitin ligase. Reiter LT; Seagroves TN; Bowers M; Bier E Hum Mol Genet; 2006 Sep; 15(18):2825-35. PubMed ID: 16905559 [TBL] [Abstract][Full Text] [Related]
34. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome. Copping NA; Silverman JL Mol Autism; 2021 Feb; 12(1):9. PubMed ID: 33549123 [TBL] [Abstract][Full Text] [Related]
35. Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome. Avagliano Trezza R; Sonzogni M; Bossuyt SNV; Zampeta FI; Punt AM; van den Berg M; Rotaru DC; Koene LMC; Munshi ST; Stedehouder J; Kros JM; Williams M; Heussler H; de Vrij FMS; Mientjes EJ; van Woerden GM; Kushner SA; Distel B; Elgersma Y Nat Neurosci; 2019 Aug; 22(8):1235-1247. PubMed ID: 31235931 [TBL] [Abstract][Full Text] [Related]
36. The Angelman syndrome protein Ube3a/E6AP is required for Golgi acidification and surface protein sialylation. Condon KH; Ho J; Robinson CG; Hanus C; Ehlers MD J Neurosci; 2013 Feb; 33(9):3799-814. PubMed ID: 23447592 [TBL] [Abstract][Full Text] [Related]
37. Angelman Syndrome: From Mouse Models to Therapy. Rotaru DC; Mientjes EJ; Elgersma Y Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294 [TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome. Berg EL; Petkova SP; Born HA; Adhikari A; Anderson AE; Silverman JL Mol Autism; 2021 Sep; 12(1):59. PubMed ID: 34526125 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Samaco RC; Hogart A; LaSalle JM Hum Mol Genet; 2005 Feb; 14(4):483-92. PubMed ID: 15615769 [TBL] [Abstract][Full Text] [Related]
40. Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity. Dodge A; Willman J; Willman M; Nenninger AW; Morrill NK; Lamens K; Greene H; Weeber EJ; Nash KR Autism Res; 2021 Apr; 14(4):645-655. PubMed ID: 33474832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]